Pre-Approval Access to Novel Compounds is an Urgent Priority to Treat People with Strains of Tuberculosis that are Resistant to Bedaquiline, Linezolid, Clofazimine, and/or the Nitroimidazoles
November 13, 2024

Three-Part Webinar Series: Speed-Up, Scale-Up TB Testing
November 4, 2024

Global Tuberculosis Community Advisory Board (TB CAB) Announces New Website and New Members
September 3, 2024

Bedaquiline: what might the future hold?
July 26, 2024

Research on the treatment of rifampin-susceptible tuberculosis-Time for a new approach
July 25, 2024